Our unique antibody discovery platform for fully human antibodies, together with advanced antibody engineering capabilities, provides a pipeline for highly specific antibodies for use in therapeutics and diagnostics.
GEN-Y Biologics was formed in 2020 to license, productise and take to market superior antibody technologies derived from state-of-the-art technological platforms developed through their exclusive licensing partnership with National University of Singapores’s highly prestigious Life Sciences Institute
Our technology employs a powerful method to screen human memory B cells from convalescent patients. Using a blend of bioinformatics, massive parallel sequencing and high throughput functional assays, we identify fully human monoclonal antibodies for research, therapy or diagnostics.
GEN-Y Biologics has an exciting pipeline of other development opportunities beyond the SARS-CoV-2 and Dengue assets. However, the initial focus for investment is on the Dengue portfolio – a portfolio that has the potential to represent a new paradigm in care of this infectious tropical disease.
Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker MULTI sales and from the early introduction of the Dengue Point of Care diagnostic arriving late 2022/early 2023.
A fast, sensitive and specific Multiplex ELISA test for SARS-CoV-2 Neutralization
The ImTracker MULTI COVID-19 Viral Variant Neutralization Test is a serological enzyme-linked immunosorbent assay (ELISA) intended for the quantitative detection of neutralizing antibodies that block binding of the host receptor angiotensin converting enzyme-2 (ACE-2) to the receptor binding domain (RBD) of SARS-CoV-2.